AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 21, 2025 in the securities class action first filed by the Firm.

ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

SAN FRANCISCO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- AstraZeneca, the British-Swedish pharmaceutical giant, is facing a securities class action lawsuit in the U.S. alleging the company misled investors about its business practices in China, a critical market that accounts for roughly 13% of its revenue.

AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption – Hagens Berman

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) and certain of its officers.

AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN

NEW YORK , Dec. 24, 2024 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public. So What: If you purchased AstraZeneca securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN

NEW YORK, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.

Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC (AZN)

NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

AstraZeneca PLC (LSE:AZN) has pulled a marketing authorisation application for its key lung cancer drug in the European Union. FTSE 100-listed AstraZeneca noted on Tuesday that it had voluntarily withdrawn the application for datopotamab deruxtecan after feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

AstraZeneca pulls lung cancer drug application in EU

AstraZeneca said on Tuesday it had voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision drug for treatment of a type of lung cancer.

AstraZeneca withdraws application for lung cancer drug in EU

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of t.

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Investors can contact the law firm at no cost to learn more about recovering their losses

AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses; February 21, 2025 Deadline to file Lead Plaintiff Motion

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZeneca class action lawsuit. Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZeneca class action lawsuit charges AstraZeneca and certain of AstraZeneca's top executives with violations of the Securities Exchange Act of 1934.

AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead the AstraZeneca Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for AstraZeneca PLC investors under the federal securities laws. To join the AstraZeneca class action, go to https://rosenlegal.com/submit-form/?case_id=1331 or call Phillip K.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN

AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.

AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC

AstraZeneca PLC's (LSE:AZN) Tagrisso has been approved in Europe for treating adults with non-small cell lung cancer (NSCLC) that cannot be removed by surgery. The approval is for patients whose tumours have an EGFR mutation, a change in their DNA that helps cancer grow.

AstraZenca's Tagrisso approved in Europe for rare lung cancer

Emerson Electric

HSBC Holdings

ITV PLC

Micron Technology

Nordea Bank Abp

Nintendo

Bank OZK

Persimmon PLC

Schlumberger

Vale S.A.

Waste Management

Bloomberg Intelligence analysts identified 50 watchable companies for 2025, focusing on potential catalysts like new leadership and geopolitical impacts, with 37 paying dividends. Fourteen of these dividend-paying companies meet the "Dogcatcher" ideal, with annual dividends from a $1K investment exceeding their single share prices. Analysts estimate net gains of 15.68% to 48.08% from top dividend focus companies by December 2025, with Vale S.A. projected to net the highest returns.

4 Ideal Buys From 15 'Safer' Dividends On Bloomberg's 50 December 2025 Watchlist

U.K.-based pharmaceutical giant AstraZeneca (AZN 1.41%) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as well as several other top executives -- were arrested following fraud-related investigations by the authorities.

Is AstraZeneca Stock a Buy?

NEW YORK, NY / ACCESSWIRE / December 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AZN STOCK ALERT: Levi & Korsinsky Notifies AstraZeneca PLC Investors of an Ongoing Investigation

Astrazeneca (AZN) closed at $65.35 in the latest trading session, marking a +1.41% move from the prior day.

Why Astrazeneca (AZN) Outpaced the Stock Market Today

NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

ATTENTION AZN SHAREHOLDERS: Investors who Lost Money on AstraZeneca PLC are Urged to Contact Levi & Korsinsky about an Ongoing Investigation

AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug importation, and personal information breaches. The probe has caused AstraZeneca American Depositary Shares to decline sharply and raised serious concerns about the company's business practices in one of its largest markets.

AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman

Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AstraZeneca Plc 2024" company profile has been added to ResearchAndMarkets.com's offering.

AstraZeneca Digital Transformation Strategy Profile 2024 - Accelerators, Incubators and Innovation Programs

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

News for AstraZeneca Stock (AZN)